Table 4 Studies concerning the immunogenicity of hexavalent vaccination in preterm
Author (year) | Study | Number of children | Gestational age (EG) in weeks (s) | Sed | Vaccine | Target | Results | Bias |
|---|---|---|---|---|---|---|---|---|
Vermeulen et al. (2013) | Prospective cohort observation | 68 • 22 immunized with vaccine cellulare (Pw) • 24 immunized with 2-component acelular vaccine (Pa-2) • 22 immunized with 3-component acelular vaccine (Pa-3) | < 31 s | Belgium | 3 types: Pw, Pa-2, Pa-3 | Evaluate the 1-year specific cellular response in the preterm by cytokine secretion after antigenic stimulation | • More than half of the preterm vaccinated with Pw or Pa-2 develops a response at 3 and 6 months • IFNɤ to FHA and PT • No effect of the booster dose on FHA or PTinduced IFNzione secretion in the 3 groups • The Pa vaccine induces a greater secretion of Th2 cytokines in response to FHA and PT, compared to children vaccinated with Pw | Limited sample |
Omeñaca et al. (2011) | Prospective | 286 | • Group I: 27–30 s • Group II: 31–36 s • Group III: ≥ 37 s | Spain, Greece | PHiD-CV Co-administration DTPa, IPV, HBV, Hib, PCV | Evaluate the immunogenicity of PHiD-CV at 2, 4, 6 months by evaluating the antibody titre as OPA or GMC 1 month after the primary vaccy cycle and 1 month after the booster dose | One month after the primary vaccination cycle and the booster dose, all bambinii serum were protected against the antigens of vaccini coadministered | |
Omeñaca et al. (2011) | Phase IIIb perspective, controlled, multicentric | 309 | • 56 group I: ≤ 31 s • 107 group II: 32–36 s • 150 group III: ≥ 37 s | Spain | Hib-MenC-TT to 2, 4, 6 months and 16–18 months Co-administration DTPa, IPV, HBV, Hib, PCV, rotavirus | Evaluate the immunogenicityof Hib-MenC-TT in preterm by measuring the specific antibody titer 1 month after the third dose and 1 month after the booster dose | • The percentage of subjects with a concentration of anti-PRP antibodies compatible with seroprotection is ≥99% in all groups • The booster dose induces a marked increase in anti-PRP GCM, after a reduction in the percentage of subjects with seroprotective titres before the booster dose • At least 97.5% of the subjects in each group have concentrations of anti-H Bs antibodies > 10 mIU / mL at 1 month after the third vaccination dose • The titer of anti-HBV antibodies after dose 3 is significantly lower in preterm than group I compared to those born with larger EGs | |
Klein et al. (2010) | Observational perspective | 88 33 ≤ 33 s 50 ≥ 37 s | ≤ 31.3–39.5 s | United States of America | DTPa, IPV, HBV, Hib PCV co-administration | Compare the humoral and cellular response of preterm vs full term babies after the primary vaccination cycle | • Preterms and those born at term develop comparable levels of memory response of T cells to type 3 polioviruses • With regard to lympho-monocellular proliferation Preterms present less frequently a positive stimulation index compared to those born at term (p = 0.03) • All subjects have serumprotective antibody titers for the 3 types of poliovirus • The GMC towards the sierotipo 1 polio was significantly lower in pretermiit compared to those born to ter mines | |
Omeñaca et al. (2010) | Prospective trial | 182 | 93 < 37 s 89 ≥ 37 s | Spain | DTPa, IPV, HBV, Hib | Evaluate the response to hepatitis B vaccine in preterm after the primary vaccination cycle and the booster dose | • 93.4 and 95.2% of preterm and full-term babies respectively show seroprotection against HBV after the primary vaccination cycle • The GMCs for HBV after primary cycle are lower in the Group of preterm born than in the group of term births, although not in a statistically significant manner • 6 preterm (6.59%) respond neither to the primary cycle nor to the booster dose • Non-responders have an EG ≤ 31 s of which 2 are severe IUGR |